Valor202020212022202320242025TTMGastos comerciales, generales y administrativos5.32 M7.25 M6.48 M6.07 M7.44 M4.29 M—Investigación y desarrollo17.29 M21.13 M20.79 M20.78 M16.65 M7.99 M—Beneficio operativo24.81 M30.95 M26.94 M26.51 M22.21 M14.03 M—Total de ingresos no operativos———————Gastos por intereses, netos de intereses capitalizados———————Ingresos no operativos, una vez deducidos los gastos por intereses———————Ingresos/gastos extraordinarios———————Beneficio antes de impuestos26.17 M30.43 M29.75 M25.99 M18.05 M13.5 M—Participación en los beneficios———————Impuestos32 K13 K90 K33 K9 0001 000—Participación minoritaria2.83 M2.65 M3.21 M2.08 M1.57 M658 K—Otros ingresos/gastos después de impuestos———————Beneficio neto antes de actividades interrumpidas26.21 M30.45 M29.84 M25.95 M18.05 M2.15 M—Operaciones suspendidas—————5.67 M—Beneficio neto26.21 M30.45 M29.84 M25.95 M18.05 M7.83 M—Ajuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas———————Beneficio básico por acción———————Beneficio por acción diluido———————Número medio de acciones ordinarias———————Acciones diluidas———————EBITDA-24.24 M————-9.42 M—EBIT-24.24 M-30.19 M-26.03 M-24.82 M-19.53 M-9.94 M—Costo de los ingresos574 K767 K909 K1.69 M2.68 M4.09 M—Otros costes de producción———————Amortización y depreciación (flujo de caja)0————522 K—
Evogene Ltd
Evogene is a computational chemistry company based in Israel, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries. At the core of its technology is ChemPass AI, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. This powerful platform significantly improves success rates while reducing development time and costs. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products driven by the integration of scientific innovation with real-world industry needs.
In 2024, the company began collaborating with Google Cloud to develop an AI-powered generative model aimed at discovering small molecules for drug development and sustainable agriculture.